Pharmaceutical composition and cosmetic composition

Patent metadata

Field	Value
Publication number	US-12036245-B2
Application number	US-201917292298-A
Country	US
Kind code	B2
Filing date	Oct 4, 2019
Priority date	Nov 7, 2018
Publication date	Jul 16, 2024
Grant date	Jul 16, 2024

Abstract

Provided are a pharmaceutical composition or a pharmaceutical composition raw material, which contains supernatant from a culture medium used during culture to induce pluripotent stem cells.

First claim

What is claimed is:

1. A cosmetic composition, comprising:
a supernatant of a culture medium and
a humectant;
wherein the supernatant of the culture medium is produced by a method comprising culturing blood cells, introducing genes encoding reprogramming factors into the blood cells to produce reprogrammed blood cells, inducing iPS cells (induced pluripotent stem cells) from the reprogrammed blood cells, and subsequently recovering the supernatant of the culture medium in which the iPS cells were induced.

2. The cosmetic composition according to claim 1 , which is suitable for preventing or ameliorating formation of any of skin blemishes, skin wrinkles, and skin sagging.

3. The cosmetic composition according to claim 1 , wherein the genes are OCT3/4 (octamer binding transcription factor 3/4), KLF4 (Krüppel-like factor 4), c-MYC (cellular homolog of myelocytomatosis virus oncogene), and SOX2 (sex determining factor Y homology box 2).

4. The cosmetic composition according to claim 3 , wherein the genes are introduced by infection of a virus vector or electroporation of an episomal plasmid.

5. The cosmetic composition according to claim 1 , wherein the humectant is at least one selected from the group consisting of glycerol, 1,3-butylene glycol, propylene glycol, propanediol, pentanediol, polyquaternium, an amino acid, urea, a pyrrolidone carboxylate salt, a nucleic acid, a monosaccharide, and an oligosaccharide.

6. The cosmetic composition according to claim 1 , which is in the form of a powder.

7. The cosmetic composition according to claim 1 , which is in the form of a capsule.

8. The cosmetic composition according to claim 1 , wherein the method further comprises, after the removing of the supernatant, sterilizing the supernatant.

9. The cosmetic composition according to claim 1 , wherein the method further comprises, after the removing of the supernatant, filtering and sterilizing the supernatant.

10. The cosmetic composition according to claim 1 , wherein the culture medium is a gel culture medium.

11. The cosmetic composition according to claim 1 , wherein the blood cells comprise a peripheral blood mononuclear cell.

12. A wound treatment agent comprising:
a supernatant of a culture medium and
an anti-inflammatory agent;
wherein the supernatant of the culture medium is produced by a method comprising culturing blood cells, introducing genes encoding reprogramming factors into the blood cells to produce reprogrammed blood cells, inducing iPS cells (induced pluripotent stem cells) from the reprogrammed blood cells, and subsequently recovering the supernatant of the culture medium in which the iPS cells were induced.

13. The wound treatment agent according to claim 12 , wherein the genes are OCT3/4 (octamer binding transcription factor 3/4), KLF4 (Krüppel-like factor 4), c-MYC (cellular homolog of myelocytomatosis virus oncogene), and SOX2 (sex determining factor Y homology box 2).

14. The wound treatment agent according to claim 13 , wherein the genes are introduced by infection of a virus vector or electroporation of an episomal plasmid.

15. The wound treatment agent according to claim 12 , wherein the anti-inflammatory agent is at least one selected from the group consisting of allantoin, bisabolol, ε-aminocaproic acid, acetyl farnesylcysteine, and glycyrrhizinic acid.

16. The wound treatment agent according to claim 12 , which is in the form of a poultice.

17. The wound treatment agent according to claim 12 , wherein the method further comprises, after the removing of the supernatant, sterilizing the supernatant.

18. The wound treatment agent according to claim 12 , wherein the method further comprises, after the removing of the supernatant, filtering and sterilizing the supernatant.

19. The wound treatment agent according to claim 12 , wherein the culture medium is a gel culture medium.

20. The wound treatment agent according to claim 12 , wherein the blood cells comprise a peripheral blood mononuclear cell.

Assignees

• Tanabe Koji
• I Peace Inc

Inventors

• Tanabe Koji
• Suto Kenta

Classifications

• A61Q19/08

  Anti-ageing preparations · CPC title

• A61P17/14 Primary

  for baldness or alopecia · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61Q7/00

  Preparations for affecting hair growth · CPC title

• A61K8/982

  Reproductive organs; Embryos, Eggs · CPC title